RCS - Cambridge Cognition - New digital health contract worth over £700,000

Cambridge Cognition HoldingsAnnouncement

21/12/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201221:nRSU2496Ja&default-theme=true

RNS Number : 2496J  Cambridge Cognition Holdings PLC  21 December 2020

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition wins new digital health contract worth over £700,000

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it has
won a new contract with a major pharmaceutical client to provide digital
assessments of mood and cognition for a depression trial. The contract is
worth over £700,000 with most of the revenue expected to be recognised in
2021.

 

Impairments in cognition can persist after recovery from a period of
depression and this can contribute to difficulties in reaching a full
recovery. So, in efforts to thoroughly assess treatment efficacy, Cambridge
Cognition has been contracted to deploy remote assessments of mood and
cognition over a 12-month period. The assessments will be delivered on
patients' mobile phones with their performance and wellbeing monitored by the
pharmaceutical client.

 

The inclusion of remote and brief assessments during both the core and
extension periods of the trial will provide the client with a better
understanding of the relationships between mood, cognition and recovery.
Cambridge Cognition is in a unique position to support the delivery of this
trial with expertise in both gold-standard cognitive assessment and innovative
digital health solutions for frequent, remote testing.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are excited to be working with another pharmaceutical company that
recognises the importance of frequent objective cognitive assessments in the
development of treatments for central nervous system disorders. This new
contract further validates the Company's strategy as again we will be
configuring existing digital health solutions rather than undertaking bespoke
software development. It also further highlights the opportunity available to
Cambridge Cognition to provide remote, patient-centred solutions in the CNS
market."

 

For further information, contact:

 

 Cambridge Cognition Holdings PLC             Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer       press@camcog.com (mailto:press@camcog.com)

 Nick Walters, Chief Financial Officer
 finnCap Ltd (NOMAD and Joint Broker)         Tel: 020 7220 0500

 Geoff Nash / Simon Hicks                     (Corporate Finance)

 Alice Lane / Sunila de Silva                 (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)       Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)       Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a neuroscience technology company developing digital
health products to better understand, detect and treat conditions affecting
brain health. The company's software products assess cognitive health in
patients worldwide to improve clinical trial outcomes, identify and stratify
patients early and improve global efficiency in pharmaceutical and healthcare
industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLBDDRUDDGGG